In contrast, engineered anti-CEA antibody fragments based on T84.66, such as scFvs, diabodies, and minibodies, have been developed to address these limitations by providing faster clearance and higher tumor to background ratios, as observed in multiple preclinical studies [20, 24, 31, 34]. Here, CEACAM5 is linked to neoplasm.